Navigation Links
Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55
Date:10/26/2011

and unpredictability inherent in our industry, while at the same time meeting or exceeding expectations for more than four consecutive years and consistently delivering strong results. With three quarters of the year completed, we are tightening our 2011 adjusted diluted EPS guidance range to $1.98 to $2.02, and are retaining our midpoint of $2.00 per share, excluding any potential contribution from the generic version of Doryx®, 150 mg. While this product is currently the subject of a preliminary injunction, the Federal Circuit has granted an expedited appeal with oral arguments scheduled for November 22, 2011. We are confident that we will prevail in the litigation and believe generic Doryx now represents a potential upside opportunity in the current year. Looking ahead, we reaffirm our compound annual growth targets of 15% top-line and 20% bottom-line, culminating in projected adjusted diluted EPS of $2.75 by the end of 2013."

Financial SummaryTotal third party revenues for the quarter ended September 30, 2011, increased $220.6 million, or 16.3% to $1.58 billion from $1.36 billion in the comparable prior year period. Total revenues include both net revenues and other revenues from third parties. Third party net revenues for the current quarter were $1.57 billion compared to $1.34 billion for the prior year quarter, representing an increase of $227.3 million, or 16.9%. Other third party revenues for the current quarter were $3.4 million compared to $10.1 million in the prior year quarter, a decrease of $6.7 million. Revenues in the current quarter were favorably impacted by the effect of foreign currency translation, generally reflecting a weaker U.S. dollar as compared to the currencies of the other major markets in which Mylan operates.  Translating third party net revenues for the current quarter at prior year comparative period exchange rates would have resulted in year-over-year growth in third party net revenues, excluding foreign curren
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
2. Life Technologies Announces Third Quarter 2011 Results
3. Insmed to Host 2011 Third Quarter Earnings Conference Call
4. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
5. Anthera Announces Third Quarter 2011 Financial Report and Conference Call
6. Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2011 Financial Results Webcast and Conference Call
7. Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40
8. HeartWare Schedules Third Quarter Conference Call and Webcast
9. Dyadic International Announces Date and Time of Third Quarter 2011 Financial Results Release and Conference Call
10. United Therapeutics Corporation to Announce Third Quarter 2011 Financial Results Before Market Open on Thursday, October 27, 2011
11. Sangamo BioSciences Announces Third Quarter 2011 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 Yuma Regional Cancer ... complementary therapies brings comprehensive cancer care to Yuma, ... Regional Cancer Center has officially opened. A Mayo ... includes services such as open, semi-private and private ... Cancer Society Resource Center, hematology, rehabilitation center, a ...
(Date:7/30/2014)... 2014  Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), ... proprietary technologies are used to discover, develop, manufacture ... bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, ... as Vice President and Chief Financial Officer. Tom ... information technology operations for Dyadic and will succeed ...
(Date:7/30/2014)... DIEGO , July 30, 2014   Epic ... designs and develops novel diagnostics to personalize and advance ... appoint of Gregory T. Lucier as chairman ... chairman and CEO of Life Technologies (formerly Invitrogen). Mr. ... as Epic commercializes its circulating rare cell analysis platform ...
(Date:7/30/2014)... , July 30, 2014  RXi ... a biotechnology company focused on discovering, developing ... medical needs using RNA-targeted technologies, today announced ... with RXI-109, for the reduction of recurrence ... surgery, has been initiated. Logo ...
Breaking Biology Technology:Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5
... anthrax that is more effective and easier to administer than ... mice and guinea pigs, report University of Michigan Medical School ... , The scientists were able to trigger a strong immune ... a nanoemulsion a suspension of water, soybean oil, alcohol ...
... engineers assemble spacecraft, have joined hot springs, ice ... scientists have discovered ultra-hardy organisms collectively known as ... recent NASA study have never been detected anywhere ... led the study conducted at NASAs Jet Propulsion ...
... method for culturing mammalian neurons in chambers not much larger ... of the neurons at very low densities, an essential step ... of individual brain cells. , The technique is described this ... Lab on a Chip. , This finding will be ...
Cached Biology Technology:Anthrax vaccine produces immunity with nanoparticles, not needles 2Anthrax vaccine produces immunity with nanoparticles, not needles 3NASA study will help stop stowaways to Mars 2Microfluidic chambers advance the science of growing neurons 2Microfluidic chambers advance the science of growing neurons 3
(Date:7/30/2014)... University Press (OUP) is pleased to announce its new ... in 2015, OUP and CINP will partner to publish ... as a fully open-access journal. , Alan Frazer, Editor-in-Chief ... the size and expertise of OUP will further facilitate ... one of the very leading journals within neuropsychopharmacology. The ...
(Date:7/30/2014)... York , July 30, 2014 ... on Global Government Biometric Systems Market 2014-2024 ... The Global Biometric Systems Market 2014-2024" offers ... systems market over the next ten years, alongside ... detailed market size forecasts. To view ...
(Date:7/30/2014)... help Americans make better decisions about what they eat, ... proposed significant changes to the Nutrition Facts label found ... article in Chemical & Engineering News (C&EN), ... explains the suggested updates and the fight that ... C&EN, points out that while the Nutrition Facts label ...
Breaking Biology News(10 mins):OUP to partner with the International College of Neuropsychopharmacology 2Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 2Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 3Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 4Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 5Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 6Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 7Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 8Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 9Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 10
... bird in hand is worth two in the bush may ... the lab of ASU School of Life Sciences Professor Roy ... at the Biodesign Institute. There, associate research scientist ... targets to develop a vaccine against a leading poultry disease, ...
... working gene is inserted into a cell to replace a ... the prevention and treatment of disease. Now a ... a counterintuitive approach also holds promise. The targeted removal of ... would do -- can restore cellular function in cells with ...
... United Kingdom and France have identified four separate ... Creutzfeldt-Jakob disease. The study, published March 14th in ... subgroups could represent distinct prion strains in what ... Prion diseases are transmissible neurodegenerative disorders characterized by ...
Cached Biology News:Solving an avian scourge could also provide benefits to human health 2Solving an avian scourge could also provide benefits to human health 3Work with power grids leads to cell biology discovery 2Work with power grids leads to cell biology discovery 3
Anti-BAR Immunogen: Peptide of aa 3-21 from human Bar Available Date: 38226...
... the HECT protein, E6-AP and ... suggests that this E2 is ... of non-""N-end rule"" protein substrates ... proteins as well as the ...
Anti-Mouse D011.10 TCR, Biotin (Clone KJ1-26) (mouse IgG2a)...
Reacts with methylated DNA from plants and vertebrates...
Biology Products: